Ellis Investment Partners’s Novavax NVAX Stock Holding History

Ellis Investment Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-150	Closed	-$2K	–	554
2022 Q3	$2K	Hold	150	–	–	﹤0.01%	724
2022 Q2	$7K	Hold	150	–	–	﹤0.01%	637
2022 Q1	$11K	Hold	150	–	–	﹤0.01%	610
2021 Q4	$21K	Buy	150 +50	+50%	+$8.59K	﹤0.01%	531
2021 Q3	$20K	Hold	100	–	–	0.01%	514
2021 Q2	$21K	Hold	100	–	–	0.01%	505
2021 Q1	$18K	Hold	100	–	–	0.01%	506
2020 Q4	$11K	Buy	+100	New	+$10.6K	﹤0.01%	560

Other funds holding NVAX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

HIG

Herr Investment Group Austin, Texas $1.5B AUM 29.27% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ellis Investment Partners's NVAX Position: Q4 2022 in Review

Ellis Investment Partners sold out of Novavax (NVAX) in Q4 2022, closing a stake of 150 shares — an estimated $2K sold.

Ellis Investment Partners first reported a position in NVAX in Q4 2020 and held it in 8 quarters. The position peaked at $21K in Q4 2021. 252 funds tracked by Wall St. Rank hold NVAX as of Q4 2022.

Ellis Investment Partners reported no remaining Novavax position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 150 Novavax shares in Q4 2022, an estimated $2K.
Ellis Investment Partners first reported a position in Novavax in Q4 2020 and held it in 8 quarters.
Ellis Investment Partners's Novavax position peaked at $21K in Q4 2021.
252 funds tracked by Wall St. Rank held Novavax as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.